// App-Quantinova.ai

: Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.

Researchers

Presenter

  • Marie-France Savard

Principal Investigators

  • J Connor Wells

  • Jeffrey Graham

  • John A. Steinharter

  • Bradley Alexander McGregor

  • Frede Donskov

  • Georg A. Bjarnason

  • Ulka N. Vaishampayan

  • Aaron Richard Hansen

  • Marco Adelmo James Iafolla

  • Giovanni Zanotti

  • Lynn Huynh

  • Mei Sheng Duh

  • Daniel Yick Chin Heng

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Aarhus University Hospital, Aarhus, Denmark

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Karmanos Cancer Institute, Detroit, MI

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Pfizer Inc, New York, NY

  • Analysis Group, Inc., Boston, MA

Locations

  • Canada

  • United States

  • Denmark

Companies

  • PharmAbcine Inc.

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Blood/haematological Diseases

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Metastatic Renal Cell Cancer

  • Hypercalcaemia

  • Solid malignancies

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Sunitinib

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved